# Evaluate the Efficacy and Safety of Atorvastatin Combined With Temozolomide in the Treatment of Glioblastoma

> **NCT06327451** · PHASE2 · RECRUITING · sponsor: **Tianjin Medical University General Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Glioblastoma, IDH-wildtype

## Interventions

- **DRUG:** Atorvastatin 20mg

## Key facts

- **NCT ID:** NCT06327451
- **Lead sponsor:** Tianjin Medical University General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-01
- **Primary completion:** 2026-02-28
- **Final completion:** 2027-02-28
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2024-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06327451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06327451, "Evaluate the Efficacy and Safety of Atorvastatin Combined With Temozolomide in the Treatment of Glioblastoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06327451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*